Intellia Therapeutics appoints Edward Dulac as CFO; Glenn Goddard steps down June 30, 2024

Intellia Therapeutics, Inc.

Edward Dulac appointed EVP, CFO, and Treasurer, effective July 22, 2024.
Glenn Goddard steps down as CFO effective June 30, 2024; departure not related to any disagreement.
Michael P. Dube (CAO) to serve as interim principal financial officer until Dulac's start date.
Dulac receives $510K base salary, 40% target bonus, $100K sign-on bonus, and equity awards of ~$4.2M.
Board approved 2024 Inducement Plan reserving 850,000 shares for new employee equity grants.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Michael P. Dube

interim principal financial officer

NTLA · Intellia Therapeutics, Inc.

Effective: 2024-06-26
Filed: June 26, 2024, 7:59 PM ET

Michael P. Dube, the Company’s Chief Accounting Officer, will serve as the Company’s interim principal financial officer until the Start Date.

Appointed

Edward Dulac

Executive Vice President and Chief Financial Officer

NTLA · Intellia Therapeutics, Inc.

Effective: 2024-07-22
Filed: June 26, 2024, 7:59 PM ET

the Company announced the appointment, effective July 22, 2024 (“Start Date”), of Edward Dulac to serve as Executive Vice President and Chief Financial Officer (“CFO”), treasurer and principal financial officer of the Company.

Departed

Glenn Goddard

Chief Financial Officer

NTLA · Intellia Therapeutics, Inc.

Effective: 2024-06-30
Successor: Edward Dulac
Filed: June 26, 2024, 7:59 PM ET

the Company also announced that Glenn Goddard, the Company’s current CFO, will step down effective June 30, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael P. Dube was appointed as interim principal financial officer at Intellia Therapeutics, Inc..

Action: appointed
Role: interim principal financial officer

Exact text from the filing

Michael P. Dube, the Company’s Chief Accounting Officer, will serve as the Company’s interim principal financial officer until the Start Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Edward Dulac was appointed as Executive Vice President and Chief Financial Officer at Intellia Therapeutics, Inc..

Action: appointed
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

the Company announced the appointment, effective July 22, 2024 (“Start Date”), of Edward Dulac to serve as Executive Vice President and Chief Financial Officer (“CFO”), treasurer and principal financial officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Glenn Goddard departed as Chief Financial Officer at Intellia Therapeutics, Inc..

Action: stepped down
Role: Chief Financial Officer

Exact text from the filing

the Company also announced that Glenn Goddard, the Company’s current CFO, will step down effective June 30, 2024.

View on SEC.gov

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-168545

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.